Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Human Ebola virus species and compositions and methods thereof
US9790473B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9790473-B2 |
| Application number | US-201514694036-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 23, 2015 |
| Priority date | Oct 24, 2008 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
First claim
Opening claim text (preview).
The invention claimed: 1. An immunogenic composition comprising: a protein consisting of an amino acid sequence of: at least 70 contiguous residues of the amino acid sequence of SEQ ID NO: 9(GP); and an immunostimulatory adjuvant present in an amount that increases an immune response to the immunogenic composition in a subject. 2. The immunogenic composition of claim 1 , wherein the protein consists of at least 80 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 3. The immunogenic composition of claim 1 , wherein the protein consists of at least 100 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 4. The immunogenic composition of claim 1 , wherein the protein consists of at least 150 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 5. The immunogenic composition of claim 1 , wherein the protein consists of at least 200 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 6. The immunogenic composition of claim 1 , wherein the protein consists of at least 300 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 7. The immunogenic composition of claim 1 , wherein the protein consists of at least 400 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 8. The immunogenic composition of claim 1 , wherein the protein consists of at least 500 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 9. The immunogenic composition of claim 1 , wherein the protein consists of at least 600 contiguous residues of the amino acid sequence of SEQ ID NO: 9. 10. The immunogenic composition of claim 1 , wherein the protein consists of the amino acid sequence of SEQ ID NO: 9. 11. An immunogenic composition comprising: a protein comprising an amino acid sequence at least 75% identical to SEQ ID NO: 9; and an immunostimulatory adjuvant present in an amount that increases an immune response to the immunogenic composition in a subject. 12. The immunogenic composition of claim 11 , wherein the protein consists of an amino acid sequence at least 80% identical to SEQ ID NO: 9. 13. The immunogenic composition of claim 11 , wherein the protein consists of an amino acid sequence at least 85% identical to SEQ ID NO: 9. 14. The immunogenic composition of claim 11 , wherein the protein consists of an amino acid sequence at least 90% identical to SEQ ID NO: 9. 15. The immunogenic composition of claim 11 , wherein the protein consists of an amino acid sequence at least 95% identical to SEQ ID NO: 9.
Assignees
Inventors
Classifications
Viruses · CPC title
oral/gastrointestinal · CPC title
avirulent or attenuated · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
expressing foreign proteins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9790473B2 cover?
- Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.
- Who is the assignee on this patent?
- The United States As Represented By The Secretary Dept Of Health And Human Services, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).